

VIRAL HEPATITIS C CASE REPORT



Acute Communicable Disease Control 313 N. Figueroa St., Rm. 212, Los Angeles, CA 90012 213-240-7941 (phone) 213-482-4856 (facsimile) www.lapublichealth.org/acd

www.iapublicnealtn.org/acd	W.Iapublicnealth.org/acd												
PATIENT INFORMATION													
Patient Name - Last First					Middle		Date of Birth		Age				
Address - Number, Street					City			State		Zip Co	de		
Telephone Number Home W	/ork			Cell		Email			Country of Birth		Date of Arrival		
Patient's current gender identity? (check one)						•	nale/Trans Wom		Patient's sex at Male F Other:	emale [☐ Non-		
Patient's sexual orientation? (check one) Gay or Lesbian Bisexual Straight or Heterosexual Not sure Something else: Don't understand the question Prefer not to answer													
Patient's race or ethnicity? (ch. White Hispanic/Latir Some other race; specify: If Asian or Native Hawaiian.	no/Spanis	sh origin	□ ві		Refused	_			n Native		/Other	Pacific Islander	
Occupation, school, and/or vol	unteer (c	ity/zip co	ode)			Homeless?	Yes No	o Ser	nsitive Occupation/	Situation (S	.O.S)?	Yes No	
CLINICAL INFORMA	TION												
Diagnosis date:					Did the patie	ent visit the en	nergency room f	or illnes	s? Yes I	No 🗌 Unk	known		
Was patient jaundiced? Ye		ю 🔲 U	nknown		Was the pati	the patient hospitalized for hepatitis? Medical Record No.							
If Yes, start date:					☐ Yes ☐	Yes No Unknown If Yes, add hospitalization details.							
Did patient have symptoms other than jaunuice:				Facility/Hospital Name:									
☐ Yes ☐ No ☐ Unknown If Yes, onset date: ☐ What symptoms?				Admit date	Disch			atient stay in an int (CCU)?					
☐ Abdominal Pain ☐ Dark Urine ☐ Diarrhea								_					
Allolexia Clay stools Fevel					If female: Pi	regnant? L	」Yes No	∐ Unki	nown If Yes, due	date:			
☐ Headache ☐ Nau☐ Fatigue ☐ Mal			_l Vomit _l Myalg	•	Did the patie	ent develop fu	lminant hepatitis	?	Yes No L	Jnknown			
☐ Joint pain ☐ Oth	er (speci	fy):			Did the patie	ent die from he	epatitis?	s □ No	Unknown If	Yes, date o	f death:		
VACCINE HISTORY Look up c	ase in CA	IR and/o	r review o	other immuniza	tion records and	d indicate whe	ther they received	the 2 do	ose or 3 dose vaccin	e series.			
	Yes	No	Unk	If Yes	s, vaccine type	/name	2 or 3 dose se	eries?	1 st Dose Date	2 nd Dose	Date	3 rd Dose Date	
Hepatitis A vaccine							2 🛮 3						
Hepatitis B vaccine							2 □ 3						
If ≤18 Years and not vaccinated, specify why not vaccinated:													
_	Reason for testing: (check all that apply) Symptoms of acute hepatitis Blood/organ donor screening												
☐ Evaluation of abnormal liver biochemistries/liver function tests ☐ Prenatal screening													
Exposure to case													
Routine screening of patient (physical exam, MD visit, pre-op)													
LABORATORY INFORMATION (Check all tests performed and attach laboratory results.)													
Hepatitis A Diagnostic Tests	;				Positive	Negative	Borderline	Not Teste	Unknown	Specimen	Collect	ion Date	
Total antibody to hepatitis A vii	•		•										
IgM antibody to hepatitis A virus (IgM anti-HAV)													
Hepatitis A virus PCR (HAV PO	CR)												
into generape		_											

Patient Name (Last, Firs	Patient Name (Last, First) Date of Birth IRIS ID:							IRIS ID:	
LABORATORY INFORMATION – Continued (Check all tests performed and attach laboratory results.)									
		<u> </u>	Positive	Negati	ve Bo	rderline	Not	Unknown	Specimen Collection Date
Hepatitis B Diagnostic Tes Total antibody to hepatitis B		IBc)					Tested		·
IgM antibody to hepatitis B	= '	•	П						
Hepatitis B surface antigen		•	П						
Antibody to hepatitis B surfa	-		_	_		_	_		
Hepatitis B e antigen (HBeA	,								
Antibody to hepatitis B e and									
	,								
Hepatitis B Nucleic Acid Tes	ST (NAT) (HBV DNA)								
Hepatitis C Diagnostic Tes	sts								
Antibody to hepatitis C virus									
Hepatitis C Nucleic Acid Tes									
HCV genotype									
Other Viral Hepatitis Diagi									
Antibody to hepatitis D virus	(IgM anti-HDV)								
Hepatitis D Nucleic Acid Tes	st (NAT) (HDV RNA)								
Antibody to hepatitis E virus	(IgM anti-HEV)								
Hepatitis E Nucleic Acid Tes	st (NAT) (HEV RNA)								
Liver enzyme results at time	of diagnosis:								
	ction date:	ALT (SGP	T)	AS	ST (SGOT)	То	tal Bilirubin _	
Peak liver enzyme results:									
ALT (SGPT)		men collection date			AST (SC	GOT)		Specimen c	ollection date:
Total Bilirubin _	Specir	men collection date	e:						
LINKAGE TO CARE									
If patient is HCV RNA positive, was the patient linked to HCV care? Yes No Unknown If Yes, HCV treatment start date:									
PUBLIC HEALTH I	NURSING INITIAI	ASSESSM	ENT AN	ID EVAL	UATIC	N			
If acute hepatitis (check here), please complete the remainder of this form. See Page 5 for acute hepatitis C definition.									
	If NOT acut	e hepatitis (check	here 🔲), p	lease go to	Final Dia	gnosis se	ection and co	mplete.	
INFECTION TIMEL	INE								
Incubation period: 2 weeks			nraaant in t	ha blaad					
Infectious period: Transmi Post-exposure prophylaxi	•	that HCV RNA IS	present in t	ne blood.					
If symptomation	c, enter date of onset*	in onset box. If Count backwa						of first positi	ive test in onset box.
		EXPOSURE		rinne proi	оаые ехр	osure p	erioa.		
		EXFOSORE	PERIOD						
Days from onset:	-6 months				-14	days	ON:	SET*	
Calendar dates:	-0 months				-14	uuys			
(month/day/year)									
								onset of Jauno	lice or onset of symptoms if not jaundiced
						on or no	on-injectio		h the HCV-infected person)
Name Relationship		Age		Recommen Provided	dation			Com	ments
·			Yes	No	Unk				
				_					

Patient Name (Last, First) _				Date of Bi	rth	IRIS	3 ID: _			
EPIDEMIOLOGIC RIS	SK FACTORS (Re	efer to Infection	Timeline abo	ove)						
During the INCUBATION PE	ERIOD: If YES, ask pa	tient when and r	ecord addition	nal details in Remarks sec			Yes	No	Unk	
Was the patient a contact of a person with confirmed or suspected acute or chronic hepatitis C virus infection?										
If Yes, contact type: Sexual Household (Non-sexual) Injection drug use Occupation Other:										
Did the patient have an accidental stick or puncture with a needle or other object contaminated with blood?										
If Yes, date: Did the patient have other exposure to someone else's blood?							_	_	_	
If Yes, date:								Ш	Ш	
During the INCUBATION PE		nte/procedures i	n hoalthoara f	facilities indicate dates 9	facility details below					
Did the patient receive blood	-	-		•	•					
Did the patient receive an organ (transplant)? Did the patient undergo hemodialysis?							_			
Did the patient undergo her										
Did the patient have any ou										
Did the patient receive any			-							
Did the patient have dental										
Did the patient have surgery	_									
Did the patient receive finge										
Did the patient have any po										
Did the patient receive chen										
Did the patient undergo acu	•									
Was the patient a resident of a long-term facility (e.g. nursing home)?									Ш	
If only risk factors are healthcare treatments/procedures, notify ACDC about potential healthcare acquired infection. During the INCUBATION PERIOD: If any procedures in other exposure sites, indicate dates & details below.								No	Unk	
Did the patient have any pa							Yes			
If Yes, where was the piercing performed? Commercial parlor/shop Correctional facility Other:										
Did the patient receive a tattoo?										
If Yes, where was the tattooing performed? Commercial parlor/shop Correctional facility Other:										
Did the patient have a manicure or pedicure?										
Did the patient have any other treatment or cosmetic procedure that penetrated the skin (e.g. head or neck shave)?										
If Yes, specify						_				
EACILITY OF OTHER DOS	SSIBI E EVDOSIIDE	SITE DETAILS								
FACILITY OR OTHER POSSIBLE EXPOSURE SITE DETAILS Facility/Site Name Facility/Site Type Facility/Site Location Date of 1st procedure Date last seen at Description						Descrip	cription of procedure			
	(clinic, hospital, etc.)	(address, locati	ion, phone #)	Or seen at facility/site	facility/site		expos			
Did the patient inject drugs no	at proceribed by a deet	or?					Yes	No	Unk	
Did the patient use street dru										
Did the patient use street dru	gs but not inject:						Ш	Ш	Ш	
Drug Name			Route of Adm	ninistration						
(e.g.: smoked, snorted, injected, taken by mouth)					l					
Was the nationt incorporated	for longer than 24 have	re?								
Was the patient incarcerated If Yes, what type of facil	-		_	☐ Juvenile facility			Ш	Ш	Ш	
ii i es, what type of facil	ny (Grieck all triat appl)	/). LI F115011		☐ Juverille idellity						

Patient Name (Last, First)		Date of Birth	IRIS	3 ID: _		
EPIDEMIOLOGIC RISK FACTORS - Continue	ed (Refer to Infection	Timeline above)				
During the INCUBATION PERIOD: If YES, ask patient when				Yes	No	Unk
Was the patient experiencing homelessness/unstable housing	?					
How many sex partners did the patient have? (Ask questions re	egardless of the patient's gen	der.)				
Number of male sex partners:	Unknown	Refused to answer				
Number of female sex partners:	☐ Unknown	Refused to answer				
Number of trans/non-binary sex partners:	Unknown	Refused to answer				
Was the patient EVER treated for a sexually transmitted disease	se?					
Was the patient EVER denied from donating blood due to hepa						
Did the patient donate blood?						
Date of last blood donation: Location	on of last donation:					
Was the patient employed in a medical or dental field involving	direct contact with human blo	ood?				
Was the patient employed as a public safety worker (firefighter,	law enforcement/correctional office	er) having direct contact with hi	ıman blood?			
Indication of recent seroconversion						
Negative Anti-HCV result within 12 months prior to HCV diagno	osis					
If Yes, collection date: Negative HCV RNA result within 12 months prior to HCV diagr	nosis					
If Yes, collection date:						
Was the patient epi-linked to known case?						
If Yes, Contact Name/Case #:						
Was the patient a part of known outbreak?						
If Yes, extent of outbreak: One CA jurisdiction Mul				ш	Ы	ш
☐ Other:	•	listate 🔲 international 🔲 0	TIKHOWH			
Guer.						
REMARKS (Please explain any YES answers in Epide	emiologic Risk Factor sec	tion. Please sign your note	s.)			
			0	4 C=		
			Suspecte	u sour	æ	
Educated patient according to B-73 on the following:	Mode of Transmission:	Prevention:	Other:	•		
	☐ Blood to Blood ☐ Sexual ☐ Maternal Infant Transmission	☐ Household Contacts ☐ Personal Hygiene on	☐ Treati	ment		

Patient Name (Last, First)	Date of Bir	th	IRIS ID:			
FINAL DIAGNOSIS						
Acute Hepatitis C: Unable to locate (UTL) Confirmed Could not confirm: Specify. Probable Chronic Hepatitis C Not acute or chronic hepatitis C (False)	Acute Hepatitis C Case Definition: Confirmed Acute: Must have the following: 1) Jaundice OR total bilirubin levels ≥3.0 2) HCV NAT positive OR HCV antigen* p. 3) Absence of a more likely diagnosis OR		IU/L			
Does this case meet the binational case definition? Yes No Unknown Binational Case Definition:	Any of the following for HCV seroconversion: Detection of anti-HCV within 12 months (365 days) of a negative anti-HCV test result OR Detection of HCV NAT within 12 months (365 days) of a negative anti-HCV test result OR Detection of HCV NAT within 12 months (365 days) of a negative HCV NAT test result in a person without a prior diagnosis of hepatitis C					
Any individual with a confirmed or probable case of a notifiable infectious disease, and: 1) Who has recently traveled or lived in Mexico, or had recent contact with persons who lived or traveled in Mexico; OR 2) Who is thought to have acquired the infection in Mexico or have been in Mexico during the incubation period of the infection and was possibly contagious during this period; OR 3) Who is thought to have acquired the infection from a product from Mexico; OR 4) Whose case requires the collaboration of both countries for the purposes of disease investigation and control.	OR Reinfection: At least 2 sequential documented negative HCV detection tests at least 12 weeks apart in someone with a prior hepatitis C diagnosis followed by a positive HCV detection test. Probable Acute: Must have the following: 1) Jaundice OR total bilirubin levels ≥3.0 mg/dL OR ALT levels >200 IU/L 2) Detection of anti-HCV 3) HCV NAT not done 4) Absence of a more likely diagnosis *When and if a test for HCV antigen(s) is approved by FDA and available.					
Investigator's name (print)	Investigator's signature	Date	Telephone number			
Health District	Supervisor signature	Area Medical Director's si	gnature			